Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
126 hedge funds and large institutions have $516M invested in Intra-Cellular Therapies Inc. in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 32 reducing their positions, and 16 closing their positions.
136% more call options, than puts
Call options by funds: $51.7M | Put options by funds: $21.9M
44% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 32
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
10% more capital invested
Capital invested by funds: $470M → $516M (+$46.9M)
1% less funds holding
Funds holding: 127 → 126 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$28.8M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$19.3M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$7.93M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.17M |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
+$3.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.4M |
| 2 |
SC
Samlyn Capital
New York
|
-$4.24M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.8M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$1.79M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.62M |
ITCI Hedge Fund Activity: Q2 2019 in Review
126 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2019, worth a combined $516M — up 10% from $470M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ITCI positions and 16 closed out — a net gain of 2 holders — while 46 added to existing stakes and 32 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $28.8M. The largest seller was Millennium Management, cutting an estimated $7.4M.
- 126 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2019, down from 127 in Q1 2019.
- Funds reported $516M of Intra-Cellular Therapies Inc. stock for Q2 2019, up 10% quarter-over-quarter.
- 18 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2019 and 16 closed out, a net change of +2 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2019 was Bellevue Group, an estimated $28.8M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2019 was Millennium Management, an estimated $7.4M sold.
Based on aggregated 13F filings for Q2 2019.